Dr. Jagannath on Next-Generation Approaches in Multiple Myeloma

Sundar Jagannath, MD, professor of Medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses upcoming agents in multiple myeloma.

Sundar Jagannath, MD, professor of Medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses next-generation approaches in multiple myeloma.

Therapeutic options in multiple myeloma are rapidly expanding, says Jagannath. In 2015, 4 new agents were approved by the FDA as treatments for patients with relapsed/refractory multiple myeloma: panobinostat, elotuzumab, daratumumab, and ixazomib.

These agents can be safely used in combination with other existing drugs, he says. At the 2015 ASH Annual Meeting, the results of a study combining lenalidomide, daratumumab, and the checkpoint inhibitor pembrolizumab were presented. This combination was able to put patients who were refractory to currently approved agents into remission, says Jagannath.

Related Videos
View All
Related Content